The use of rapid respiratory pathogen (RRP) testing among children with influenza-like illness (ILI) did not reduce antibiotic prescribing, according to a randomized clinical trial published late last week in JAMA Network Open.
Implementation of a test that provides rapid bacterial identification and susceptibility results from positive blood cultures shortened the time to optimal antibiotic therapy and reduced unnecessary antibiotic exposure in hospitalized patients with bacteremia, researchers reported late last week in the Journal of Antimicrobial Chemotherapy.
A rapid, cartridge-based polymerase chain reaction (PCR) platform developed by scientists at Johns Hopkins University for detecting gonorrhea infections and providing antibiotic susceptibility results showed promising results in a study published this week in Science Translational Medicine.
CARB-X announced today that it is awarding up to $3 million to GenomeKey of Bristol, United Kingdom, to develop an innovative rapid diagnostic test for sepsis.
A study today in the journal Family Practice reports that a rapid, multi-viral point-of-care test for respiratory infections was easy to use, acceptable to patients and clinicians, and appeared to influence clinical reasoning about antibiotics.
The introduction of a rapid diagnostic test (RDT) in conjunction with antimicrobial stewardship (AMS) activities and infectious disease (ID) consultation at an academic tertiary medical center was associated with shortened time to optimal antibiotic therapy in patients with bloodstream infections, University of Maryland researchers reported in Open Forum Infectious Diseases.
In a prospective study, the test accurately predicted patients who could be cured with the oral antibiotic.
The National Institutes of Health (NIH) today awarded $19 million for a new diagnostic test that can detect gonorrhea in under 30 minutes—and determine if the infection is susceptible to a single-dose antibiotic. The test is made by Visby Medical, Inc.
CARB-X announced an award today of up to $1.82 million to French biotechnology company Eligo Bioscience to develop CRISPR- and bacteriophage-based therapeutics to prevent multidrug-resistant infections in transplant patients.
The implementation of a rapid diagnostic testing platform at a children's hospital, coupled with real-time antibiotic stewardship program (ASP) result notification, was associated with improved antibiotic management of hospitalized children with gram-positive blood culture isolates, researchers reported today in Infection Control and Hospital Epidemiology.
